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OBJECTIVES: Hepatitis C (HCV) can lead to serious and costly liver complications 
including hepatocellular carcinoma and liver transplantation. Physicians have 
employed a “watch and wait” philosophy, placing their HCV patients in “ware-
houses” depending on disease genotype (GT), waiting for disease progression 
or the launch of new treatments. There has been a significant amount of press 
behind the high prices of new HCV products, but little has been discussed about 
the cumulative clinical and economic value they bring. One aspect of value is 
clinical benefit as measured by sustained viral response (SVR) rate. The objective 
was to determine how the average efficacy, measured by SVR, of HCV treatments 
changed from November 2013 to April 2014 and its potential impact on clinical 
and economic outcomes. METHODS: Using IMS Health National Prescription Audit 
Data, two time periods were defined: the past state of November 2013, when the 
fewest number of prescriptions for HCV treatments were written; the current 
state of April 2014, when the greatest number of prescriptions for HCV treatments 
were written. In order to compare the average SVR rate in these two time points, 
we calculated a weighted average SVR rate across GTs based on the proportion of 
patients in each GT and the market share of the following products: sofosbuvir, 
telaprevir, simeprevir, and boceprevir. RESULTS: Combining SVR rates with market 
share and the proportion of patients in each GT, the average SVR rate in November 
2013 and April 2014 was 74% and 86%respectively. This 12% increase across GTs 
was presumably driven by the launch of sofosbuvir. CONCLUSIONS: There are 
significant clinical and economic implications of overall improvement in SVR 
rate including impacts on liver transplant hospitalizations and end of life care. 
Additional HEOR considerations related to linking SVR rates to these outcomes 
will be considered further in the poster.
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OBJECTIVES: Assess the clinical effect of clostridial collagenase ointment (CCO) 
relative to undifferentiated wound dressings in the outpatient care setting for the 
treatment of venous leg ulcers (VLU). METHODS: Retrospective de-identified elec-
tronic medical records from 2007-2013 were extracted from the Intellicure Limited 
Data Set (I-LDS). The I-LDS extracts records from 96 hospital-based outpatient 
wound centers. A propensity score model using a 3 to 1 nearest neighbor match-
ing approach was performed to test for treatment effect and adjust for covariance 
between that received CCO and wounds treated with undifferentiated wound dress-
ings. RESULTS: A total of 9,314 patients, 22,312 wounds, and 186,023 visits for VLU 
were identified. The majority of patients was female (51.9%) with an average age of 
61.6 (SD= 17.7). Approximately 21.3% had a history of hypertension, 8.3% had a his-
tory of venous insufficiency with diabetes, and 2.5% received immunosuppressive 
agents. The mean wound surface area was 7.9cm2 (SD= 14.4). The average wound 
age was 8.5 months (SD= 27.8) and the average treatment duration was 2.9 months 
(SD= 4.9). Of the 22,312 wounds, approximately 13.2% received CCO (n= 2,954). The 
average number of CCO tubes used by patients was 2.6 (SD = 1.2). The average total 
visits where CCO was administered was 5.6 (SD = 16.2) and the average days of use 
with CCO was 12.3 (SD = 41.3). VLUs treated with CCO were significantly more likely 
(p< 0.005) to improve over the course of therapy relative to wounds treated with 
undifferentiated wound dressings alone. CONCLUSIONS: This analysis indicates 
that CCO provides a clinical benefit in the management of VLUs. Over the course 
of therapy VLUs treated with CCO demonstrate greater clinical improvement than 
VLUs treated with undifferentiated wound dressings.
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OBJECTIVES: To indirectly estimate the relative treatment effect of 12 weeks of 
treatment with SMV versus TPV in combination with response-guided background 
therapy of 24/48 weeks of Peginterferon/ribavirine (PR) in previously untreated 
patients with genotype 1 chronic hepatitis C virus infection, using patient-level 
data from the pivotal phase III-trials. METHODS: Patient-level data from three 
phase 3 trials in treatment-naive patients were pooled: ADVANCE (12 weeks 
of TPV-treatment (T12PR24/48)) and QUEST 1&2 (12 weeks of SMV-treatment 
(SMV12PR24/48) (with PR24/48 meaning response-guided duration of PR of 24 or 
48 weeks). To adjust for potential differences in patient characteristics across both 
trials, an adjusted odds ratio (OR) for reaching sustained viral response at week 
24 (SVR24) was estimated for a multivariate logistic regression model, includ-
ing genotype (G1a vs G1b), liver status (F0-2 vs F3-4), race (white, black, other), 
viral load (< 273K/273-< 800K/800-< 1200K/≥ 1200K IU/ml), age (≤ 45/45< -≤ 65/> 65), 
gender and BMI (< 25/25-< 30/30+) as baseline covariates. As a sensitivity analy-
sis, a similar analysis was generated excluding SMV-G1a patients with Q80K-
polymorphism. RESULTS: Patient numbers for T12PR24/48 and SMV12PR24/48 
were 363 and 521 respectively. 16.3% (n= 85) of SMV-patients were G1a with Q80K-
polymorphism. Overall, G1a (OR vs 1b = 0.75, p= 0.01), peg-interferon alpha-2b (OR 
vs peg-interferon alpha-2a = 0.60, p= 0.03), F3-4 liver status (OR vs F0-F2= 0.48, 
p< 0.0001), black race (OR vs white race = 0.56, p< 0.001) and viral load ≥ 1200K (OR vs 
< 273K = 0.28, p< 0.0001) were significantly associated with lower SVR24-rates. The 
observed SVR24-rates were 75% (TVR) versus 80% (SMV) (unadjusted OR= 0.75). The 
adjusted OR for T12PR24/48 to reach SVR24 compared to SMV12PR24/48 was 0.64 
[95% CI: 0.46;0.91] (p= 0.0113). When excluding Q80K-positive patients, the adjusted 
OR was 0.45 [0.31;0.67] (p< 0.0001). CONCLUSIONS: In absence of H2H-comparison 
of telaprevir versus simeprevir in treatment-naive patients, an adjusted indirect 
commonly used antibiotics to manage cSSSI (vancomycin, linezolid, daptomycin, 
tigecycline). METHODS: This retrospective study was conducted using the Premier’s 
Perspective Comparative Database (2010-2013), which includes over 170 million 
inpatient records from ~500 hospitals in the US. Hospitalization records for adults 
(≥ 18 years) with a diagnosis of cSSSI (identified using ICD-9-CM codes) were selected. 
cSSSI-related hospitalization records with evidence of intravenous ceftaroline, vanco-
mycin, daptomycin, linezolid or tigecycline were included. Using four separate logistic 
regression models propensity scores were estimated and patients in ceftaroline group 
were matched with patients in vancomycin, daptomycin, linezolid and tigecycline 
groups separately. Outcomes including LOS, inpatient costs and in-hospital mortality 
were compared among patients in ceftaroline group with the 4 other antibiotic groups 
using unadjusted (t-test and chi-square tests) tests. RESULTS: The sample sizes in the 
matched cohorts were as follows: a) ceftaroline/ vancomycin n= 2,834 (each group); 
b) ceftaroline/daptomycin n= 2,651; c) ceftaroline/tigecycline n= 2,606; d) ceftaroline/
linezolid n= 2,554. Mean duration for the study antibiotics ranged from 3.9 (vanco-
mycin) to 4.6 (tigecycline) days. Average LOS and inpatients costs were significantly 
(all P-values < 0.001) lower among patents in the ceftaroline group compared with 
patients in the vancomycin (mean LOS: 5.1 vs. 5.6;costs: $8,051 vs. $10,089), linezolid 
(LOS: 5.1 vs. 6.4;costs: $8,081 vs. $12,020), daptomycin (LOS: 5.0 vs. 6.3;costs: $7,824 vs. 
$10,227), tigecycline (LOS: 5.2 vs. 6.1;costs: $8,264 vs. $11,353) groups. In-hospital mor-
tality rate was ~1% for ceftaroline, vancomycin, tigecycline and daptomycin groups 
(except linezolid group 2%). CONCLUSIONS: Previously two-large global clinical trials 
(CANVAS 1 and 2) confirmed clinical efficacy of ceftaroline in-comparison with vanco-
mycin (standard-of-care) among patients with cSSSI. The current study serves as an 
initial-step towards confirming real-world effectiveness of ceftaroline in comparison 
with other commonly used antibiotics for cSSSI.
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OBJECTIVES: New influenza vaccines were developed to improve vaccine effec-
tiveness by expanding influenza B coverage and boosting hemagglutinin (HA) 
concentration. This research aims to assess the health impact of the new vac-
cines – high dose (HD) and quadrivalent influenza vaccines (IIV4), instead of IIV3, 
in adults aged 65 and older under Ontario’s Universal Influenza Immunization 
Program (UIIP). METHODS: An analytical model of one flu season was developed 
using Ontario’s physician visits and ED uses, and Canadian influenza hospitaliza-
tion and mortality rates with three age cohorts (age 65-74, 75-84, and 85 and above) 
at two levels of health risks (high and low). Ontario’s demographic data was from 
Statistics Canada. Vaccine efficacy and effectiveness against health outcomes were 
based on published studies. Sensitivity analyses with extreme values of all relevant 
parameters were conducted. RESULTS: Use of HD in place of IIV3 would avert 13,271 
influenza cases (range: 4,648-23,161) and 2,483 symptomatic non-consulting cases 
(range: 690-5,226) annually, and decrease health care utilization significantly – 3,818 
physician office visits (range: 1,530-5,520), 1,223 emergency department (ED) uses 
(range: 485-1,786), 772 hospitalizations (range: 442-1,223) and 341 deaths (range 
195-537). These reductions in health outcomes would avoid 857 outpatient antiviral 
treatments (range: 0-2,192) and eliminate 4,546 days of lost productivity (range: 
1,387-10,054) among Ontario’s elderly residents a year. IIV4 also showed a reduction 
in influenza-related health outcomes – 4,900 influenza cases (range: 3,364-11,817), 
1,178 symptomatic non-consulting cases (range: 499-2,665), with 102 hospitaliza-
tions (range: 51-175) and 33 deaths (range 17-57) avoided annually; as a result, 1,623 
(623-3,928) work days loss were prevented. CONCLUSIONS: Although potential net 
health impact would fluctuate annually depending on the variability of influenza 
viruses, both HD and IIV4 are expected to attain significant to modest reductions 
in influenza-associated morbidity and mortality in seniors. Those findings were 
proven to be robust in sensitivity analyses.
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OBJECTIVES: Analyze the relationship of clinical efficacy and trough concentration 
of Vancomycin treatment on Neonatal Bacterial Sepsis according to the high trough 
concentration standards. METHODS: Totally 73 neonates with bacterial sepsis were 
selected in our hospital. Their clinical information,labotatory results and patho-
gens were collected. Statistical analysis of the clinical efficacy, bacterial clearance 
rate and plasma concentration data after vancomycin treatment. RESULTS: The 
clinical total effective rate and bacterial clearance rate were 86.30% and 91.78%.
The average trough concentration of vancomycin was(12.57±6.83)mg·L-1 . The rate 
of reaching the high trough concentration standards was only 41.1%. Compared 
to < 10mg·L-1, the bacterial clearance rate and clinical efficacy of trough concen-
tration in 10-20mg·L-1 were much higher (P= 0.013, P= 0.001). 24 cases adjusted 
the dose according to the initial concentration data, but only 13 cases(54.17%)’s 
trough concentrations were in the standard range. CONCLUSIONS: Clinical efficacy 
of Vancomycin has a good correlation with trough concentration. But the rate of 
reaching the high trough concentration standard was low and TDM is needed for 
individualized therapy regimen.
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